Clinical trial
Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.
NCT00270491 · ARCAGY/ GINECO GROUP, Other · Completed
Key facts
| NCT number | NCT00270491 |
|---|---|
| Title | Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer. |
| Official title | A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer. |
| Lead sponsor | ARCAGY/ GINECO GROUP, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Paclitaxel, Capecitabine |
| Enrollment | 130 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2010 |
| First posted | Dec 28, 2005 |
| Last update posted | Feb 25, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: